Cargando…
Brentuximab vedotin use in pediatric anaplastic large cell lymphoma
Anaplastic large cell lymphoma (ALCL) is the most common type of mature T-cell non-Hodgkin lymphoma in children/adolescents. ALCL is characterized by expression of CD30 in the neoplastic lymphoid cells with frequent expression of anaplastic lymphoma kinase (ALK), especially within the pediatric popu...
Autores principales: | Agrusa, Jennifer E., Egress, Emily R., Lowe, Eric J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232850/ https://www.ncbi.nlm.nih.gov/pubmed/37275877 http://dx.doi.org/10.3389/fimmu.2023.1203471 |
Ejemplares similares
-
Brentuximab Vedotin in Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma
por: Tsang, Vivian
Publicado: (2012) -
Frontline brentuximab vedotin in breast implant‐associated anaplastic large‐cell lymphoma
por: Alderuccio, Juan Pablo, et al.
Publicado: (2018) -
Improvement of Cutaneous Anaplastic Large Cell Lymphoma by Brentuximab Vedotin Monotherapy
por: Onaka, Takashi, et al.
Publicado: (2018) -
Cutaneous Anaplastic Large-Cell Lymphoma with Dramatic Response to Brentuximab Vedotin
por: Şahin, Mustafa, et al.
Publicado: (2021) -
Patient-reported outcomes of brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma
por: Chen, Robert, et al.
Publicado: (2016)